The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.

导出 OA

翻译打印收藏纠错

作者： Jujuan,Wang ^[1] ; Dongjiao,Wang ^[1] ; Qingbo,Zhang ^[2] ; Limin,Duan ^[3] ; Tian,Tian ^[3] ; Xiaoyan,Zhang ^[1] ; Jianyong,Li ^[1] ; Hongxia,Qiu ^[4]

作者单位： Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China. ^[1] Department of PET-CT Centre, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China. ^[2] Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China. ^[3] Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China. qiuhongxia@njmu.edu.cn. ^[4] Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, China. qiuhongxia@njmu.edu.cn. ^[5]

关键词 Chemotherapy Differential diagnosis Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHLH)PET–CT Prognosis